Null Results in Brief
No Association between Smoking and the Presence of Tobacco-specific
Nitrosamine Metabolites in Ovarian Follicular Fluid
Sara J. Matthews, Stephen S. Hecht, Helen M. Picton,
Ming Ye, Steven G. Carmella, Susan Shires,
Christopher P. Wild,
1
and Alastair W. M. Hay
Molecular Epidemiology Unit, Epidemiology and Health Services Research,
School of Medicine [S. J. M., S. S., C. P. W., A. W. M. H.] and Department
of Obstetrics and Gynaecology [H. M. P.], University of Leeds, United
Kingdom and University of Minnesota Cancer Center, Minneapolis, Minnesota
55455 [S. S. H., M. Y., S. G. C.]
Introduction
The TSNA
2
NNK is a rodent carcinogen likely to play an
important role in smoking-induced lung cancer (1). Metabolism
of NNK can proceed directly via cytochrome P450 activation to
-hydroxyNNK or formation of NNAL and subsequent -
hydroxylation to -hydroxyNNAL, resulting in formation of
promutagenic DNA adducts. NNAL can be detoxified by con-
jugation to NNAL-Gluc. NNAL and NNAL-Gluc in body flu-
ids are accurate biomarkers of tobacco smoke carcinogen ex-
posure in humans (1). NNK is found in cervical mucus of
women who smoke, possibly contributing to risk of developing
cervical carcinoma (2), and smoking reduces pregnancy rates in
women having assisted reproduction. We tested the hypothesis
that NNK metabolites are elevated in the follicular fluid of
smokers. If so, DNA damage may occur, possibly resulting in
germ-line mutations in oocytes, increased risk of ovarian car-
cinogenesis, or poor outcomes during IVF.
Materials and Methods
“Clean catch” (minimal blood contamination) specimens of
follicular fluid were collected from women undergoing trans-
vaginal oocyte recovery as part of an IVF program. Samples
were centrifuged (1200 rpm
2
, 10 minutes, 4°C) to remove
cellular debris, cryopreserved, and stored at -70°C until anal-
ysis. Smoking status was assessed by questionnaire and by
high-performance liquid chromatography measurement of sal-
ivary cotinine in women and their male partners and follicular
fluid cotinine (3). Twenty-two follicular fluid samples (12
smokers and 10 nonsmokers) blinded as to cotinine status were
shipped on dry ice from Leeds, United Kingdom to the Uni-
versity of Minnesota Cancer Centre for analysis of NNAL and
NNAL-Gluc by gas chromatography with nitrosamine-selective
detection (limit of detection, 9 fmol/ml in 5 ml of follicular
fluid) (4). The hospital ethics committee approved the research
protocol, and all subjects gave written informed consent.
Statistical Analysis. The study was conducted to test whether
NNAL and NNAL-Gluc could be identified in the follicular
fluid. These metabolites are specific to tobacco-exposed indi-
viduals. In the study of Lackmann et al., (4) the mean level of
NNAL plus NNAL-Gluc in urine from newborn children whose
mothers smoked was 0.062 pmol/ml (95% confidence interval
0.035– 0.11), and a nominal mean value of half the detection
limit (0.01 pmol/ml) was assigned to the children of nonsmok-
ers. Assuming similar data in the current study, the numbers of
subjects used would detect a significant difference between the
groups (P 0.01) with a power of 90%.
Results
Patients in the smoking group reported smoking 20 ciga-
rettes/day (mean 10 cigarettes/day). Cotinine was detected in
the saliva and follicular fluid of all apart from one self-reported
smoker (Table 1). There was a strong correlation at the indi-
vidual level between the two measures (r = 0.88; n = 22; P
0.01). Overall, concentrations of cotinine in follicular fluid
were about half those seen in saliva. Two patients in the
self-reported nonsmoking group also had significant amounts
of cotinine, in the same range as the smokers. NNAL was
detected at a low level (0.049 pmol/ml) in only 1 of 22 follicular
fluid samples, and this was from a nonsmoker, negative for
cotinine analysis.
Study Limitations. The study has two principal limitations:
(a) it involves relatively small numbers of women, however,
these women were selected as heavy smokers (confirmed by
cotinine data) undergoing IVF and represent a group which are
now relatively rare and, therefore, difficult to recruit, and (b)
the method of detection of NNAL and NNAL-Gluc may not be
sensitive enough for follicular fluid analysis; however, one
sample did contain detectable levels, and the method has been
shown to be sensitive enough to measure these metabolites even
in the urine of children exposed transplacentally to NNK (4).
Discussion
This study demonstrates that levels of the NNK metabolites are
likely to be low in the mature Graafian follicles of smokers. The
1 patient with a detectable level of NNAL was a self-reported
nonsmoker. However, the cotinine assay used may not detect
low levels of exposure to passive smoking, and indeed, earlier
studies have detected some subjects with detectable urinary
NNAL-Gluc in the absence of cotinine (4). Animal studies have
suggested that the presence of tobacco-related polycyclic aro-
matic hydrocarbons is associated with oocyte maturation de-
fects (5), but no studies have investigated the presence of
TSNA in the human ovary. The absence of NNK metabolites
from the ovary, in the presence of cotinine, may reflect low
Received 10/5/01; revised 10/5/01; accepted 12/20/01.
The costs of publication of this article were defrayed in part by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1
To whom requests for reprints should be addressed, at Molecular Epidemiology
Unit, Epidemiology and Health Services Research, School of Medicine, Univer-
sity of Leeds, Leeds LS2 9JT, United Kingdom. Phone: (0044)|113|233|6602;
Fax: (0044)|113|233|6603; E-mail: c.p.wild@leeds.ac.uk.
2
The abbreviations used are: TSNA, tobacco-specific N-nitrosamine; NNK,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNAL, 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol; NNAL-Gluc, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol glucuronide; IVF, in vitro fertilization.
321 Vol. 11, 321–322, March 2002 Cancer Epidemiology, Biomarkers & Prevention
on December 7, 2021. © 2002 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from